Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 47.68 Million EUR | -22.93% |
| 2022 | 61.86 Million EUR | -2.49% |
| 2021 | 63.44 Million EUR | -8.29% |
| 2020 | 69.18 Million EUR | 1056.31% |
| 2019 | 5.98 Million EUR | -24.72% |
| 2018 | 7.94 Million EUR | 82.08% |
| 2017 | 4.36 Million EUR | 224.54% |
| 2016 | 1.34 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 57.27 Million EUR | 0.0% |
| 2023 Q3 | 47.68 Million EUR | -16.75% |
| 2023 Q1 | 57.27 Million EUR | -7.42% |
| 2023 FY | 47.68 Million EUR | -22.93% |
| 2023 Q4 | 47.68 Million EUR | 0.0% |
| 2022 Q1 | 72.96 Million EUR | 15.01% |
| 2022 Q2 | 72.96 Million EUR | 0.0% |
| 2022 Q3 | 60.72 Million EUR | -16.77% |
| 2022 FY | 61.86 Million EUR | -2.49% |
| 2022 Q4 | 61.86 Million EUR | 1.87% |
| 2021 Q1 | 63.98 Million EUR | -7.51% |
| 2021 FY | 63.44 Million EUR | -8.29% |
| 2021 Q4 | 63.44 Million EUR | 0.0% |
| 2021 Q3 | 63.44 Million EUR | -0.84% |
| 2021 Q2 | 63.98 Million EUR | 0.0% |
| 2020 Q4 | 69.18 Million EUR | 0.0% |
| 2020 Q3 | 69.18 Million EUR | -3.66% |
| 2020 Q1 | 20.49 Million EUR | 242.52% |
| 2020 FY | 69.18 Million EUR | 1056.31% |
| 2020 Q2 | 71.81 Million EUR | 250.43% |
| 2019 Q3 | 5.98 Million EUR | 0.0% |
| 2019 Q4 | 5.98 Million EUR | 0.0% |
| 2019 FY | 5.98 Million EUR | -24.72% |
| 2019 Q1 | - EUR | 0.0% |
| 2018 FY | 7.94 Million EUR | 82.08% |
| 2017 FY | 4.36 Million EUR | 224.54% |
| 2016 FY | 1.34 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -224.14% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 85.421% |
| Adocia SA | 24.95 Million EUR | -91.06% |
| Aelis Farma SA | 26.28 Million EUR | -81.428% |
| Biophytis S.A. | 11.93 Million EUR | -299.472% |
| Advicenne S.A. | 12.4 Million EUR | -284.307% |
| genOway Société anonyme | 31.84 Million EUR | -49.741% |
| IntegraGen SA | 8 Million EUR | -495.986% |
| Medesis Pharma S.A. | 1.92 Million EUR | -2375.218% |
| Neovacs S.A. | 47.53 Million EUR | -0.31% |
| NFL Biosciences SA | 3.97 Million EUR | -1100.843% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -219.729% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -1172.589% |
| Sensorion SA | 46.49 Million EUR | -2.553% |
| Theranexus Société Anonyme | 7.23 Million EUR | -558.783% |
| TME Pharma N.V. | 2.49 Million EUR | -1814.131% |
| Valbiotis SA | 33.24 Million EUR | -43.41% |
| TheraVet SA | 7.53 Million EUR | -532.862% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -35.173% |
| argenx SE | 4.11 Billion EUR | 98.84% |
| BioSenic S.A. | 9.55 Million EUR | -398.807% |
| Celyad Oncology SA | 16.28 Million EUR | -192.845% |
| DBV Technologies S.A. | 165.65 Million USD | 71.216% |
| Galapagos NV | 4.35 Billion EUR | 98.906% |
| Genfit S.A. | 173.87 Million EUR | 72.577% |
| GeNeuro SA | 6.31 Million EUR | -655.295% |
| Innate Pharma S.A. | 184.19 Million EUR | 74.114% |
| Inventiva S.A. | 69.13 Million EUR | 31.036% |
| MaaT Pharma SA | 42.93 Million EUR | -11.064% |
| MedinCell S.A. | 36.94 Million EUR | -29.049% |
| Nanobiotix S.A. | 93.89 Million EUR | 49.22% |
| Onward Medical N.V. | 43.62 Million EUR | -9.287% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 55.397% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 41.781% |
| Oxurion NV | 6.55 Million EUR | -627.954% |
| Pharming Group N.V. | 426.33 Million EUR | 88.816% |
| Poxel S.A. | 4.82 Million EUR | -888.617% |
| GenSight Biologics S.A. | 9.08 Million EUR | -424.717% |
| Transgene SA | 45.21 Million EUR | -5.449% |
| Financière de Tubize SA | 1.92 Billion EUR | 97.517% |
| UCB SA | 15.53 Billion EUR | 99.693% |
| Valneva SE | 469.39 Million EUR | 89.842% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -54.663% |